Cross Country names new Chief Accounting Officer

Cross Country Healthcare, Inc. announced leadership changes in its finance and technology functions.

Accepted by SEC EDGAR 03/10/2026 - 04:12 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Cross Country Healthcare, Inc. announced leadership changes in its finance and technology functions. Effective March 10, 2026, James V. Redd III will step down as Senior Vice President and Chief Accounting Officer, and Phil Noe will step down as Chief Information Officer. The company states that neither departure results from any dispute or disagreement, including on accounting practices or financial reporting.

The Board appointed longtime employee Marvin Veizaga as Senior Vice President and Chief Accounting Officer, effective the same date. Veizaga has been with the company since 2015 in increasingly senior controller roles and previously worked as a Senior Auditor at Deloitte & Touche LLP. Under a new Letter Agreement, his base salary will be $340,000, with an annual short-term incentive bonus target of 50% of base salary and an annual long-term equity incentive target of 50% of base salary. The company notes there are no related-party arrangements or family relationships tied to his appointment.

Insights

Corporate governance analyst

Routine leadership reshuffle with internal promotion to principal accounting role.

The company is transitioning both its Chief Accounting Officer and Chief Information Officer roles while promoting from within for the key accounting position. Appointing Marvin Veizaga, an internal candidate with a decade-long tenure and prior audit experience, supports continuity in financial reporting.

Compensation terms for Veizaga include a $340,000 base salary and incentive targets tied at 50% of base pay for both cash and equity. The filing explicitly states the departures are not due to disputes, which helps limit concern about accounting issues. Future disclosures in periodic reports will show how this leadership change aligns with the company’s financial reporting quality.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did Cross Country Healthcare (CCRN) announce on March 9–10, 2026?

Cross Country Healthcare announced that James V. Redd III will cease serving as Senior Vice President and Chief Accounting Officer and that Phil Noe will cease serving as Chief Information Officer, both effective March 10, 2026, while appointing Marvin Veizaga as the new Chief Accounting Officer.

Why did Cross Country Healthcare’s principal accounting officer and CIO leave their roles?

The company stated that neither James V. Redd III’s departure as Chief Accounting Officer nor Phil Noe’s departure as Chief Information Officer resulted from any dispute or disagreement, including over accounting practices or financial reporting, indicating these are not being characterized as conflict-driven exits.

Who is Marvin Veizaga, the new Chief Accounting Officer at Cross Country Healthcare (CCRN)?

Marvin Veizaga is a long-tenured Cross Country Healthcare executive, employed since 2015 and most recently serving as Group Vice President, Corporate Controller. He previously held assistant and business unit controller roles and earlier worked as a Senior Auditor at Deloitte & Touche LLP, and is a certified public accountant.

What are the compensation terms for Cross Country Healthcare’s new Chief Accounting Officer?

Under a Letter Agreement effective March 10, 2026, Marvin Veizaga’s base salary is set at $340,000. He is eligible for an annual short-term cash incentive bonus targeting 50% of base salary and an annual long-term equity incentive award also targeting 50% of base salary.

Are there any related-party or family relationships tied to Marvin Veizaga’s appointment at CCRN?

The filing states there is no arrangement or understanding with any other person behind Marvin Veizaga’s appointment, no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K, and no family relationships with any of the company’s directors or executive officers.

Where can investors find the full terms of Marvin Veizaga’s Letter Agreement with Cross Country Healthcare?

The complete Letter Agreement with Marvin Veizaga, dated March 10, 2026, is filed as Exhibit 10.1. The company notes the summary is qualified in its entirety by reference to this exhibit, which is incorporated by reference in the same report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000114110300011411032026-03-092026-03-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 9, 2026

CROSS COUNTRY HEALTHCARE INC

(Exact name of registrant as specified in its charter)

DE		000-33169		13-4066229
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5201 CONGRESS AVENUE, SUITE 160

BOCA RATON, Florida 0

(Address of principal executive offices, including zip code)

(561) 237-4152

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.0001 per share	CCRN	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Principal Accounting Officer and Named Executive Officer

On March 9, 2026, it was determined that, as of March 10, 2026 (the “Effective Date”), James V. Redd III will cease to serve as the Senior Vice President and Chief Accounting Officer of Cross Country Healthcare, Inc. (the “Company”) and that Phil Noe will cease to serve as Chief Information Officer of the Company. Neither Mr. Redd’s departure nor Mr. Noe’s departure was the result of any dispute or disagreement with the Company, including with respect to any matters relating to the Company’s accounting practices or financial reporting.

 Appointment of Principal Accounting Officer

On March 9, 2026, the Company’s Board of Directors appointed Marvin Veizaga as its Senior Vice President, Chief Accounting Officer (the “Appointment”), with such Appointment to be effective as of the Effective Date. Mr. Veizaga, 45, has been employed with the Company since 2015, most recently serving as its Group Vice President, Corporate Controller. From 2021 to 2023, he served as the Company’s Vice President, Assistant Controller, and from 2020 to 2021, he was the Company’s Vice President, Business Unit Controller. Prior to joining the Company, Mr. Veizaga served as a Senior Auditor at Deloitte & Touche LLP from 2012 to 2015. Mr. Veizaga is a certified public accountant and holds a Bachelor of Science in Accounting from Florida Atlantic University.

In connection with the Appointment, the Company and Mr. Veizaga entered into that certain Letter Agreement, dated as of March 10, 2026 (the “Letter Agreement”). Pursuant to the Letter Agreement, effective as of the Effective Date, Mr. Veizaga’s base salary will be increased to $340,000, and he will be eligible for an annual short-term incentive bonus target amount of 50% of his base salary under the Company’s Annual Cash Incentive Program. The Letter Agreement also provides that Mr. Veizaga will be eligible to receive an annual long-term incentive equity award with a target value equal to 50% of his base salary.

There is no arrangement or understanding between Mr. Veizaga and any other person pursuant to which Mr. Veizaga was appointed Principal Accounting Officer, nor does he have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Veizaga has no family relationships with any of the Company’s directors or executive officers. The foregoing summary of the Letter Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 9.01                          Financial Statements and Exhibits

(d) Exhibits

Exhibit                          Description

10.1	Letter Agreement, dated March 10, 2026, by and between Cross Country Healthcare, Inc. and Marvin Veizaga
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

CROSS COUNTRY HEALTHCARE, INC.

Dated:                          March 10, 2026

By:            /s/ William J. Burns

           William J. Burns

           Executive Vice President & Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 exhibit10-1.htm 8.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB